Satellite Bio Analysis: $110M Raised
What is Satellite Bio?
Satellite Bio pioneers Tissue Therapeutics, a new category of regenerative medicine using the SAT platform to convert cell types into bioengineered tissues. The SAT platform enables durable engraftment of expanded hepatocyte cells to restore liver function. The company's approach targets diseases caused by genetic and environmental interactions, offering tailored therapies for severe, life-threatening conditions.
Location
Cambridge, United States
Employees
11-50
Founded
2019
Funding Status
Series A
Product Features & Capabilities
- SAT Platform enabling expansion, seed formation and stabilization of solid organ cells
- Tissue Therapeutics for liver function restoration
- Expandable hepatocyte cell therapy for organ repair
Use Cases
Restore liver function in patients with genetic and environmental disease interactions; Deliver tailored therapies for severe, life-threatening conditions; Enable durable engraftment of expanded hepatocyte cells; Treat diseases requiring cellular repair or organ replacement
Other Considerations
Published first preprint on expandable hepatocyte technology in bioRxiv; CEO presented at Med 2024 Cell & Gene Meeting; Co-Founders include Sangeeta Bhatia, MD, PhD and Christopher Chen, MD, PhD; Based in Cambridge, MA; Founded in 2019; Employee count: 11-50
See something that needs updating? Suggest edits to this profile.